A randomised phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme.

 

Trial Summary:

The Cabaret study aimed to measure the effectiveness of the different treatment regimens in terms of survival and wellbeing for patients with recurrent glioblastoma multiforme (a type of brain tumour).

Supported By:

Roche Products Pty Limited; NHMRC CTC; COGNO

Eligibility:

Patients with recurrent grade IV glioma (glioblastoma multiforme) who have had radiotherapy and temozolomide chemotherapy.

Registration ID:

ACTRN12610000915055

Participation:

Australia

Australian Lead Group:

COGNO

Status:

Closed

Activation Date:

05/11/2010

Chairs:

Dr Kathryn Field (AU)

Contact:

cabaret@ctc.usyd.edu.au